Although more than a decade has passed since the approval of immune checkpoint
inhibitors (ICIs) for the treatment of melanoma and non-small-cell lung, breast and …

Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …

Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment
via non-invasive tumor burden assessment. To investigate subtype-specific differences in …

Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …

Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …

Background Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is
strongly associated with favorable outcome. We examined the utility of serial circulating …

Predictive biomarkers aid selection of personalized therapy targeted to molecular alterations
within an individual's tumor. Patients' responses to targeted therapies are commonly …

Liquid biopsies (LBs), particularly using circulating tumor DNA (ctDNA), are expected to
revolutionize precision oncology and blood-based cancer screening. Recent technological …

Radiographic imaging is routinely used to evaluate treatment response in solid tumors.
Current imaging response metrics do not reliably predict the underlying biological response …

Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that
originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as …